Meeting
2018 ASCO Annual Meeting
SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
Authors
Sacha Rothschild
University Hospital Basel, Basel, Switzerland
Sacha Rothschild , Alfred Zippelius , Spasenija Savic , Michel Gonzalez , Walter Weder , Alexandros Xyrafas , Corinne Rusterholz , Miklos Pless
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02572843
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8584)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8584
Abstract #
TPS8584
Poster Bd #
188a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
First Author: Sacha Rothschild
Poster
2020 ASCO Virtual Scientific Program
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
First Author: Sacha Rothschild
Poster
2023 ASCO Annual Meeting
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
First Author: Florian Guisier
Poster
2023 ASCO Annual Meeting
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
First Author: Laetitia A Mauti